Wenman Wu
Overview
Explore the profile of Wenman Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Li L, Gao L, Wu X, Wu W, Ding Q, Wang X
Clin Appl Thromb Hemost
. 2020 Sep;
26:1076029620944471.
PMID: 32886527
The changes in the coagulation, fibrinolytic, and endothelial functions are correlated with the pathophysiology of the thromboembolic diseases during acute illness. However, these changes in patients with hereditary thrombophilia who...
22.
Lu Y, Chen Z, Dai J, Wu X, Gu H, Li Z, et al.
Blood Adv
. 2020 May;
4(9):1867-1869.
PMID: 32374877
No abstract available.
23.
Ye N, Liu Z, Wang X, Xu X, Wu W
Blood Coagul Fibrinolysis
. 2020 May;
31(5):303-309.
PMID: 32371663
: To evaluate analytic and clinical performance of plasma thrombin-antithrombin complex (TAT) and D-dimer assay in assessing the severity and outcome of acute ischemic stroke. The prospective study was conducted...
24.
Wu W, Xiao L, Wu X, Xie X, Li P, Chen C, et al.
Haematologica
. 2020 Feb;
106(1):264-268.
PMID: 32079698
No abstract available.
25.
Firrman J, Wang Q, Wu W, Dong B, Cao W, Moore A, et al.
Mol Ther Methods Clin Dev
. 2020 Feb;
17:328-336.
PMID: 32071925
It is well known that canine factor VIII (cFVIII) has a higher specific activity than does human FVIII (hFVIII), and it has been previously demonstrated that cFVIII light chain is...
26.
Wu X, Dai J, Xu X, Li F, Li L, Lu Y, et al.
Arterioscler Thromb Vasc Biol
. 2019 Dec;
40(2):483-494.
PMID: 31875702
Objective: Defective PC (protein C) pathway predisposes patients to venous thromboembolism (VTE) and is mostly, but not exclusively, attributed to hereditary PC or PS (protein S) deficiencies and activated PC...
27.
Shao Y, Wu W, Xu G, Wang X, Ding Q
Blood
. 2019 Sep;
134(20):1745-1754.
PMID: 31558466
Combined factor V (FV) and FVIII deficiency (F5F8D) is a rare autosomal-recessive bleeding disorder caused by mutations in lectin mannose binding-1 (LMAN1) and multiple coagulation factor deficiency-2 (MCFD2). Six causative...
28.
Ye N, Liu Z, Xu G, Wang X, Wu F, Xu X, et al.
Hematology
. 2019 Sep;
24(1):631-636.
PMID: 31514689
Acquired hemophilia A (AHA) is a rare disease resulting from autoantibodies against coagulation factor VIII that leads to spontaneous bleeding. This study reports the clinical characteristics and treatment outcomes of...
29.
Ma S, Chen C, Liang Q, Wu X, Wang X, Wu W, et al.
Orphanet J Rare Dis
. 2019 Jul;
14(1):182.
PMID: 31340840
Background: Inherited Factor XIII deficiency (FXIIID) is one of the most severe and under-diagnosed rare bleeding disorders. Only 5 large deletions involving one or more exons in F13A1 have been...
30.
Qu S, Xu Q, Wu W, Li F, Li C, Huang R, et al.
Chem Biol Drug Des
. 2019 May;
94(3):1664-1671.
PMID: 31108011
Rivaroxaban (RIV) is a direct oral anticoagulant (DOAC) targeting activated coagulation factor X (FXa). An earlier study reported the F174A mutant of FXa resistant to a RIV-like inhibitor, Apixaban. In...